CVAC

CureVacNasdaqGM:CVAC Stock Report

Market Cap

US$10.3b

7D

-19.3%

1Y

6.4%

Updated

20 Sep, 2021

Data

Company Financials +
CVAC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CVAC Overview

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

CureVac Competitors

Twist Bioscience

NasdaqGS:TWST

US$6.0b

Thermo Fisher Scientific

NYSE:TMO

US$234.8b

Danaher

NYSE:DHR

US$231.7b

Genscript Biotech

SEHK:1548

HK$69.5b

Price History & Performance

Summary of all time highs, changes and price drops for CureVac
Historical stock prices
Current Share PriceUS$53.30
52 Week HighUS$43.00
52 Week LowUS$151.80
Beta0
1 Month Change-20.23%
3 Month Change-8.26%
1 Year Change6.43%
3 Year Changen/a
5 Year Changen/a
Change since IPO-4.65%

Recent News & Updates

Sep 01

CureVac: Wait For Concrete News Before Investing

In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection. Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures. The cash position is also good. However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.

Shareholder Returns

CVACUS BiotechsUS Market
7D-19.3%-0.7%-2.5%
1Y6.4%25.9%33.0%

Return vs Industry: CVAC underperformed the US Biotechs industry which returned 25.9% over the past year.

Return vs Market: CVAC underperformed the US Market which returned 33% over the past year.

Price Volatility

Is CVAC's price volatile compared to industry and market?
CVAC volatility
CVAC Beta0
Industry Beta1.03
Market Beta1

Stable Share Price: CVAC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: CVAC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2000505Franz-Werner Haashttps://www.curevac.com

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens.

Valuation

Is CureVac undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CVAC ($53.3) is trading below our estimate of fair value ($142.25)

Significantly Below Fair Value: CVAC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CVAC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CVAC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CVAC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CVAC is overvalued based on its PB Ratio (11.9x) compared to the US Biotechs industry average (3.1x).


Future Growth

How is CureVac forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

54.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CVAC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CVAC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CVAC's is expected to become profitable in the next 3 years.

Revenue vs Market: CVAC's revenue (24.8% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CVAC's revenue (24.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CVAC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has CureVac performed over the past 5 years?

-29.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CVAC is currently unprofitable.

Growing Profit Margin: CVAC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CVAC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: CVAC has a negative Return on Equity (-18.15%), as it is currently unprofitable.


Financial Health

How is CureVac's financial position?


Financial Position Analysis

Short Term Liabilities: CVAC's short term assets (€1.4B) exceed its short term liabilities (€247.6M).

Long Term Liabilities: CVAC's short term assets (€1.4B) exceed its long term liabilities (€552.4M).


Debt to Equity History and Analysis

Debt Level: CVAC's debt to equity ratio (3.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CVAC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CVAC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CVAC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 137.9% per year.


Dividend

What is CureVac current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CVAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CVAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CVAC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CVAC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CVAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Franz-Werner Haas (51 yo)

1.5yrs

Tenure

€601,881

Compensation

Dr. Franz-Werner Haas, LLD, LLM, PhD, has been Chief Executive Officer of CureVac AG since June 2020 and has been its Chief Operating Officer since 2018 and also serves as its Member of Management Board. H...


CEO Compensation Analysis

Compensation vs Market: Franz-Werner's total compensation ($USD706.35K) is below average for companies of similar size in the US market ($USD11.33M).

Compensation vs Earnings: Franz-Werner's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CVAC's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: CVAC's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.2%.


Top Shareholders

Company Information

CureVac N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: CureVac N.V.
  • Ticker: CVAC
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.301b
  • Shares outstanding: 186.91m
  • Website: https://www.curevac.com

Number of Employees


Location

  • CureVac N.V.
  • Friedrich-Miescher-Strasse 15
  • Tübingen
  • Baden-Württemberg
  • 72076
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 22:35
End of Day Share Price2021/09/20 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.